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Abstract
Background: The challenge for evidence-based healthcare is to reduce mortality and the burden of diseases. This study
aimed to compare where research is conducted to where research is needed for 2 public health priorities: tobacco
consumption and HIV infection.
Methods: We identified randomized controlled trials (RCTs) included in Cochrane systematic reviews published between
1997 and 2007 and registered ongoing RCTs identified in January 2009 through the World Health Organization’s
International Clinical Trials Registry Platform (WHO-ICTRP) evaluating interventions aimed at reducing or stopping tobacco
use and treating or preventing HIV infection. We used the WHO and World Bank reports to classify the countries by income
level, as well as map the global burden of disease and mortality attributable to tobacco use and HIV infection to the
countries where the trials performed.
Results: We evaluated 740 RCTs included in systematic reviews and 346 ongoing RCTs. For tobacco use, 4% of RCTs
included in systematic reviews and 2% of ongoing trials were performed in low- and middle-income countries, even though
these countries represented 70% of the mortality related to tobacco use. For HIV infection, 31% of RCTs included in
systematic reviews and 33% of ongoing trials were performed in low- and middle-income countries, even though these
countries represented 99% of the mortality related to HIV infection.
Conclusions: Our results highlight an important underrepresentation of low- and middle-income countries in currently
available evidence (RCTs included in systematic reviews) and awaiting evidence (registered ongoing RCTs) for reducing or
stopping tobacco use and treating or preventing HIV infection.
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Introduction
The main challenge for public health policies is to reduce mortality
andtheburden of disease. This aim implies havingadequate evidence
to guide health care providers and policymakers for implementing the
most efficient and cost-effective interventions. More than two-thirds
of the world’s population live in low- and middle-income countries
[1,2], and 93% of the burden of preventable mortality occurs in these
countries [3]. The shortage of resources in low- and middle-income
countries paradoxically increases the need for reliable healthcare
evidence to prioritize the use of these scarce resources [4,5]. Such
evidence is essential to determine the prevention and therapeutic
strategies that work best but also under which circumstances they
work and how best to deliver them [6].
In this context, it could be useful to tailor research to the needs of
the particular population and to the context (socio-cultural, access to
services, etc.). Addressing context-specific questions is fundamental to
designing interventions that improve health [7,8]. Results of research
performed in high-income countries cannot be easily transposed to
low- and middle-income countries. The extent to which questions
addressed by researchers in high-income countries are relevant to
patients and physicians in low-income countries is largely unknown.
This study aimed to compare where research is conducted to where
research is needed according to the attributable burden of disease,
mortality and prevalence. We compared high-income countries to low-
or middle-income countries defined by the 2008 World Bank
classification. We considered both current available evidence (i.e.,
randomized controlled trials [RCTs] included in systematic reviews)
and awaiting evidence (i.e., RCTs registered on the World Health
Organization’s International Clinical Trials Registry Platform [WHO-
ICTRP]) that provide data for current clinical decision making and
future public health policies. We focused on 2 public-health priorities,
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16878tobacco use and HIV infection,because they are ranked among the top
5 leading causes of mortality in the world [9].
Methods
I. Classification of countries
We classified the countries according to the 2008 World Bank
classification that divides the world into income categories (low,
middle, and high) according to economies in terms of gross region
national income per capita and in geographic regions for low- and
middle-income economies only. We considered trials performed in
high-income countries (country with a per capita income of $$11
906 in 2008 [e.g., USA, European Union [EU], Canada, Australia
and other]) as one group and trials performed in low- and middle-
income countries as another group [9,10]. In addition, we grouped
low- and middle-income countries into 6 geographic regions
Figure 1. Flow diagram of Cochrane systematic reviews selected in the study and retrieval of randomized controlled trials (RCTs)
from these reviews.
doi:10.1371/journal.pone.0016878.g001
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PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e16878Figure 2. Flow diagram of reports of ongoing RCTs selected from International Clinical Trial Registries* via the World Health
Organization (WHO) portal. * International clinical trial registries: Clinicaltrials.gov, Australian New Zealand Clinical Trials Registry, Chinese Clinical
Trial Register, Clinical Trials Registry - India, German Clinical Trials Register, Iranian Registry of Clinical Trials, Japan Primary Registries Network,
International Standard Randomised Controlled Trials Number, The Netherlands National Trial Register, Sri Lanka Clinical Trials Registry.
doi:10.1371/journal.pone.0016878.g002
Table 1. Characteristics of RCTs of tobacco use and HIV infection included in selected Cochrane systematic reviews and ongoing
RCTs selected from international clinical trial registries.
Total Tobacco use HIV infection
All RCTs
Ongoing
RCTs All RCTs
Ongoing
RCTs All RCTs
Ongoing
RCTs
n=1 086 (%) n=740 (%) n=346 (%) n=668 (%) n=556 (%) n=112 (%) n=418 (%) n=184 (%) n=234 (%)
Intervention
N PT 489 (45.0) 283 (38.2) 206 (59.5) 252 (37.7) 201 (36.2) 51 (45.5) 237 (56.7) 82 (44.6) 155 (66.2)
N NPT 597 (55.0) 457 (61.8) 140 (40.5) 416 (62.3) 355 (63.8) 61 (54.5) 181 (43.3) 102 (55.4) 79 (33.8)
Number of participating countries
N 1 1 004 (92.5) 695 (94.0) 309 (89.3) 639 (95.7) 529 (95.1) 110 (98.2) 365 (87.3) 166 (90.2) 199 (85.0)
N 1–5 38 (3.5) 15 (2.0) 23 (6.7) 8 (1.2) 6 (1.1) 2 (1.8) 30 (7.2) 9 (4.9) 21 (9.0)
N 6–10 10 (0.9) 4 (0.5) 6 (1.7) 4 (0.6) 4 (0.7) 0 6 (1.4) 0 6 (2.6)
N .10 12 (1.1) 4 (0.5) 8 (2.3) 2 (0.3) 2 (0.4) 0 10 (2.4) 2 (1.1) 8 (3.4)
N Not reported 22 (2.0) 22 (3.0) -- 15 (2.2) 15 (2.7) -- 7 (1.7) 7 (3.8) --
RCTs: randomized controlled trials. PT: pharmacologic intervention. NPT: nonpharmacologic intervention.
doi:10.1371/journal.pone.0016878.t001
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and Pacific, Eastern Europe and Central Asia, Latin America and
Caribbean, Middle East and North Africa, South Asia, Sub-
Saharan Africa).
II. Where research is conducted
To describe the context (i.e., geographic region and socioeco-
nomic situation of the countries where the trial took place) of
research performed in these fields, we focused on the context of
currently available evidence and awaiting evidence that could be
used for clinical decision making. Because RCTs are the gold
standardtoassesstheeffectivenessofinterventions,weevaluatedthe
context of all RCTs included in Cochrane systematic reviews (i.e.,
context of current evidence) and all ongoing RCTs in the registries
of the WHO-ICTRP (i.e., context of awaiting evidence). We
focused on systematic reviews performed by the Cochrane
collaboration because this international, not-for-profit organisation
is a source of high-quality, reliable health information providing up-
to-date knowledge about the effects of health care. Further, an
importantgoal oftheCochrane collaborationisthe disseminationof
information to low- and middle-income countries. The Cochrane
Library is freely available to all residents of low-income countries.
a. Identification of RCTs included in Cochrane
systematic reviews. We identified all systematic reviews of
interventions aimed at reducing or stopping tobacco use and those
aimed at treating or preventing HIV infection published in the
Cochrane database of systematic reviews between January 1997
and December 2007. We searched for the following terms in the
title, abstract or the MeSH terms: ‘‘smoking cessation’’ OR
‘‘tobacco use cessation’’ OR ‘‘smoking reduction’’ OR ‘‘tobacco
reduction’’ OR ‘‘smoking abstinence’’ OR ‘‘tobacco abstinence’’
for tobacco use and ‘‘HIV’’ OR ‘‘human immunodeficiency virus’’
OR ‘‘AIDS’’ OR ‘‘acquired immunodeficiency syndrome’’ OR
‘‘sexually transmitted diseases’’ for HIV infection. Titles and
abstracts were then screened by one of us (NA) to identify the
relevant systematic reviews. The full texts for selected abstracts
were retrieved and reviewed by one of us (NA) to determine the
eligibility of systematic reviews for inclusion. Another reviewer (IB)
checked the adequate selection of the abstracts and confirmed the
adequate exclusion of full-text articles.
Reports were included if the study was identified as a systematic
review or meta-analysis of interventions aimed at reducing tobacco
consumption or preventing or treating HIV infection. We
excluded systematic reviews focusing on a specific setting, except
when this setting concerned developing countries (e.g., interven-
tion for tobacco cessation in a dental setting) or a specific
population (e.g., tobacco cessation for hospitalised patients).
Excluding these systematic reviews allowed for a relatively
homogeneous sample of systematic reviews aimed at providing
conclusions on treatment effect whatever the context. We also
excluded systematic reviews of prevention or treatment of
complications of HIV infection (e.g., opportunistic infections,
Kaposi’s sarcoma) and those evaluating an intervention for
another disease among subjects infected with HIV (e.g., treatment
of anaemia or tuberculosis infection in people with HIV infection).
b. Identification of ongoing RCTs. In January 2009, we
searched the WHO-ICTRP (http://www.who.int/trialsearch/)
for all ongoing RCTs registered in the platform’s 10 clinical
trials registries: Australian New Zealand Clinical Trials Registry
(ANZCTR), Chinese Clinical Trial Register (ChiCTR),
ClinicalTrials.gov, Clinical Trials Registry - India (CTRI),
German Clinical Trials Register (DRKS), Iranian Registry of
Clinical Trials (IRCT), International Standard Randomised
Controlled Trials Number (ISRCTN.org), Japan Primary
Registries Network, The Netherlands National Trial Register
(NTR), and Sri Lanka Clinical Trials Registry (SLCTR). We used
this platform because it allows access to all primary registries
meeting the WHO criteria and the requirements of the
International Committee of Medical Journal Editors [11].
We searched for RCTs in the ‘‘conditions’’ menu of the
platform using the topics ‘‘smoking’’ for tobacco use and ‘‘HIV
infection’’ for HIV infection and in the ‘‘recruitment’’ menu of the
‘‘advanced search’’ feature, using ‘‘recruiting’’ to select only
ongoing RCTs.
Table 2. Tobacco use: smoking prevalence, burden of disease (in disability-adjusted life-years [DALYs]), attributable mortality,
RCTs included in Cochrane systematic reviews and ongoing RCTs selected from international clinical trial registries for high-income
and low- and middle-income countries.
Countries
Attributable
DALYs
(thousands)
Attributablemortality
(thousands)
Smoking
prevalence
(millions)
Total
RCTs PT RCTs
NPT
RCTs
Total
ongoing
RCTs
PT
ongoing
RCTs
NPT
ongoing
RCTs
n=72 919
(%)
n=4 802
(%)
n=11 220
(%)
n=541
(%)
n=200
(%)
n=341
(%)
n=112
(%)
n=51
(%)
n=61
(%)
High-income countries 18 900 (25.9) 1 462 (30.4) 202 (18.0) 517 (95.6) 187 (93.5) 330 (96.8) 110 (98.2) 51 (100) 59 (96.7)
Low- or middle-income
countries
54 019 (74.1) 3 340 (69.6) 920 (82.0) 24 (4.4) 13 (6.5) 11 (3.2) 2 (1.8) 0 2 (3.3)
N East Asia and Pacific 16 518 (22.7) 1 059 (22.1) 429 (38.0) 9 (1.6) 4 (2.0) 5 (1.5) 2 (1.8) 0 2 (3.3)
N Eastern Europe and
central Asia
14 769 (20.3) 897 (18.7) 122 (11.0) 7 (1.3) 4 (2.0) 3 (0.9) 0 0 0
N South Asia 14 452 (19.8) 879 (18.3) 178 (15.0) 1 (0.2) 0 1 (0.3) 0 0 0
N Latin America and
Caribbean
3 957 (5.4) 250 (5.2) 98 (9.0) 5 (0.9) 4 (2.0) 1 (0.3) 0 0 0
N Middle east and North
Africa
2 153 (2.9) 121 (2.5) 37 (3.0) 1 (0.2) 1 (0.5) 0 0 0 0
N Sub-Saharan Africa 2 171 (3.0) 1 (0.2) 0 1 (0.3) 0 0 0
RCTs: randomized controlled trials. PT: pharmacologic intervention. NPT: nonpharmacologic intervention. GBD: global burden of disease.
doi:10.1371/journal.pone.0016878.t002
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obtained by this search to select the relevant RCTs (i.e., all RCTs
of interventions aimed at reducing or stopping tobacco
consumption or preventing or treating HIV infection).
For RCTs included in systematic reviews, we collected data on
the individual RCTs included in the review. To avoid collecting
data several times from an RCT included in several systematic
reviews, we recorded all RCTs in an EndNote data file (EndNote
for Windows Version X2, Bld (3210)). We systematically searched
this file for reports with the same authors and excluded duplicates.
If the country where the trial was performed was not mentioned
in the systematic review, we retrieved the published report for the
trial to obtain more information.
As a quality assurance exercise, another author (AD) collected
data on a random sample of 102 RCTs included in systematic
reviews.
For ongoing trials, we collected data from the trial records
available in the WHO-ICTRP and in the primary registry’s
records.
For each RCT included in a systematic review or registered, we
checked whether the trial was performed in a high-income or a
low- or middle-income country. We considered trials performed in
both high-income and low- and middle-income countries as trials
of low- and middle-income countries.
We also collected data on the intervention (pharmacological or
nonpharmacologic treatment) and the number of participating
countries.
III. Where research is needed
The following indicators were elaborated:
1. Prevalence of tobacco use and HIV infection. To
obtain the prevalence of tobacco use and HIV infection in the
world, in high-income countries and in different regions of low-
and middle-income countries, we used the World Bank reports for
number of smokers [12] and WHO reports for number of people
living with HIV infection [13,14].
2. Mortality and global burden of disease (GBD). The
global burden of disease (GBD) reflects the burden of disease by
disability-adjusted life years (DALYs). This time-based measure
combines years of life lost due to premature mortality and that lost
due to time lived in states of less than full health. The DALY
measure was developed in the original GBD 1990 study to assess
the burden of disease consistently across diseases, risk factors and
regions [15].
We used the data (WHO assessment of the GBD for 2000–2002
compiled and updated by the World Bank) related to the GBD
(DALYs) and mortality attributable to tobacco use and HIV
infection in the world, in high-income countries and in low- and
middle-income countries [16].
IV. Geographic representation
For an adequate representation of the contrast between the area
where trials are needed and the area where trials are conducted,
we constructed an area cartogram according to the method
developed by Gastner and colleagues [17]. Area cartograms are
maps in which the sizes of geographic regions such as countries are
not proportional to the area on the ground but, rather, appear in
proportion to their population or some other demographic feature
such as disease prevalence. We used such maps to compare the
area for number of people smoking and with HIV infection to
where RCTs have been and are being conducted.
Statistical analysis
We used descriptive statistics; categorical variables are described
with frequencies and percentages. All data analyses involved use of
SAS for Windows, Release 9.1 (SAS Inst., Cary, NC).
Cartographic representation was developed with use of Migratio
8.0 (Ste ´phane Le Rouzic, Migratio.fr, Rennes, France) and
ScapeToad cartography software (Cho ˆros Laboratory, EPFL-
ENAC-INTER, Lausanne, Switzerland).
Results
Where research is conducted
The flow of RCTs included in the selected systematic reviews
and ongoing RCTs through the study is in Figures 1 and 2,
respectively. The electronic search yielded 118 systematic reviews,
of which 57 (28 of tobacco use, 29 of HIV infection) were selected.
From these systematic reviews, data for 1 012 trials were retrieved;
143 duplicate reports and reports of 129 nonrandomised trials
were excluded. We included in the final analysis data for 740
RCTs (556 of tobacco use, 184 of HIV infection). Of the 940
ongoing RCTs (266 of tobacco use, 674 of HIV infection)
identified in the international clinical trial registries, we included in
the final analysis data for 346 (112 of tobacco use, 234 of HIV
infection).
The characteristics of the RCTs and ongoing RCTs are in
Table 1.
Geographic representation
Tobacco use trials. The geographic comparison of location
of RCTs of tobacco use and mortality and GBD (in DALYs)
attributable to tobacco use is in Table 2 and Figure 3A. In total,
96% of RCTs included in systematic reviews and 98% of ongoing
RCTs were performed in high-income countries. Both kinds of
trials were performed mainly in the USA (314 [57%] and 68
[61%], respectively) and the EU (144 [26%] and 27 [24%],
respectively). Only 24 (4%) RCTs included in systematic reviews
and 2 (2%) ongoing RCTs were carried out in low- or middle-
income countries, although these countries represented 74% of the
GBD (in DALYs) and 70% of the mortality attributable to tobacco
use and 82% of the smokers. Only 11 of 341 (3%) trials and 2 of 61
(3%) ongoing RCTs assessing nonpharmacologic treatment were
performed in low- and middle-income countries. The highest
prevalence of tobacco use concerns East Asia and Pacific countries
(38%). This area represents 22% of the mortality attributable to
tobacco use. In this area, only 9 RCTs were performed, and only 2
registered RCTs are ongoing. Similarly, no ongoing trial is
registered in Eastern Europe and Central Asia, South Asia, Latin
America and Caribbean, the Middle East and North Africa, and
Sub-Saharan Africa, which overall represent nearly half of the
mortality attributable to tobacco use. Figure 4 highlights the
differences in geographic representation between regions with a
high prevalence of smokers and where trials are conducted.
HIV infection trials. The geographical comparison of
location of RCTs and mortality and GBD (in DALYs)
attributable to HIV infection is in Table 3 and Figure 3B. In
total, 70% of RCTs included in systematic reviews and 67% of
Figure 3. Prevalence, burden of disease (in disability-adjusted life-years [DALYs]), attributable mortality and percentage of RCTs
included in Cochrane systematic reviews and ongoing RCTs selected from international clinical trial registries for different regions
of the world for trials of tobacco use (A) and HIV infection (B).
doi:10.1371/journal.pone.0016878.g003
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(31%) RCTs and 77 (33%) ongoing RCTs were carried out in low-
or middle-income countries, although these countries represented
99% of the GBD, 99% of the mortality and 94% of the people
with HIV infection. About 16% (16/99) of trials and 26% (20/78)
of ongoing RCTs assessing nonpharmacologic treatments were
performed in low- and middle-income countries.
Only 37 (21%) RCTs and 40 (17%) ongoing RCTs were
performed in Sub-Saharan Africa, which represents 84% of the
GBD and 84% of the mortality attributable to HIV infection and
68% of the people with HIV infection. Similarly, only 2 ongoing
RCTs are being performed in South Asia, although this area
represents 9% of the GBD, 9% of the mortality and 12% of the
people with HIV infection. Figure 5 highlights the differences in
geographic representation between the regions with a high
prevalence of people with HIV infection and where trials are
conducted.
Discussion
This study evaluated the context of clinical research (i.e., where
research is performed) for 2 public health priorities: tobacco use
and HIV infection. We described the location of 740 RCTs
included in Cochrane systematic reviews and 346 ongoing RCTs
identified through international clinical trial registries. Our results
highlight a gap between where trials are conducted and where
research is needed in terms of GBD, mortality and prevalence of
tobacco use and HIV infection. Most ongoing and RCTs were
performed in high-income countries, even though most of the
mortality and GBD concerns low- and middle-income countries.
Only 4% and 32% of the total and ongoing RCTs performed in
the fields of tobacco use and HIV infection, respectively, were
conducted in low- and middle-income countries. However, low-
and middle-income countries represent 70% and 99% of the
mortality attributable to tobacco use and HIV infection,
respectively [13,18].
The number of trials of tobacco use performed in low- and
middle-income countries was particularly low (4%) as compared
with trials of HIV infection performed in these countries (about
one-third).
Previous studies have highlighted the underrepresentation of
research addressing priority issues for low- and middle-income
countries [19]. Some authors highlighted the poor association of
GBD and reports of RCTs published in high-impact-factor
journals [19,20]. Swingler et al. [21] analysed nearly 3 000
systematic reviews and assessed the correlation between the
number of systematic reviews undertaken and the burden of
disease: only a few systematic reviews focused on some diseases
affecting a large number of the world’s population. Sheriff showed
that only 3% of mental disease research is performed in low- and
middle-income countries [22], but the religious and cultural
individuality of these countries could greatly hamper implemen-
tation of any mental health interventions recommended by
research performed in high-income countries. These low research
percentages are probably related to the limited financial
investment in research for low- and middle-income countries
Figure 4. Area cartograms showing the sizes of countries in proportion to A) the number of smokers* and B) the number of RCTs
(RCTs included in Cochrane systematic reviews and ongoing RCTs) aimed at reducing or stopping tobacco use
{. * Source: World
Bank’s 2005 World Development Indicators, 2005. Table 2.18 Health: risk factors and future challenges. The World Bank sourced this in turn from the
World Health Organization’s 2004 World Health Report, Tobacco Control Country Profiles 2003.
{ The number of RCTs (primary and ongoing) was
classified by main regions according to the 2008 World Bank classification: high-income countries, East Asia and Pacific, Eastern Europe and Central
Asia, Latin America and Caribbean, Middle East and North Africa, South Asia, Sub-Saharan Africa. For the construction of the map we divided the
number of trials performed in each region by the number of countries in each region.
doi:10.1371/journal.pone.0016878.g004
Table 3. HIV infection: AIDS prevalence, burden of disease (in disability-adjusted life-years [DALYs]), attributable mortality, RCTs
included in Cochrane systematic reviews and ongoing RCTs selected from International Clinical Trials Registries for high-income
and low- and middle-income countries.
Countries
Attributable
DALYs
(thousands)
Attributable
mortality
(thousands)
HIV infection
prevalence(thousands)
Total
RCTs PT RCTs
NPT
RCTs
Total
ongoing
RCTs
PT
ongoing
RCTs
NPT
ongoing
RCTs
n=67 568 (%) n=2 440 (%) n=33 200(%) n=177(%) n=78(%) n=99(%) n=234(%) n=156(%) n=78(%)
High-income countries 445 (0.6) 15 (0.6) 2 100 (6.3) 123 (69.5) 40 (51.3) 83 (83.8) 157 (67.1) 99 (63.5) 58 (74.3)
Low- or middle-income
countries
67 141 (99.4) 2 425 (99.4) 31 100 (93.7) 54 (30.5) 38 (48.7) 16 (16.2) 77 (32.9) 57 (36.5) 20 (25.7)
N Sub-Saharan Africa 56 795 (84.1) 2 057 (84.3) 22 500 (67.9) 37 (20.9) 29 (37.1) 10 (10.1) 40 (17.1) 28 (17.9) 12 (15.3)
N South Asia 5 846 (8.7) 214 (8.8) 4 000 (12.0) 1 (0.6) 0 0 2 (0.9) 0 2 (2.6)
N Latin America and
Caribbean
2 099 (3.1) 74 (3.1) 1 800 (5.4) 5 (2.8) 2 (2.6) 2 (2.0) 9 (3.8) 7 (4.5) 2 (2.6)
N East Asia and pacific 2 026 (2.9) 68 (2.8) 800 (2.4) 9 (5.1) 5 (6.4) 4 (4.1) 12 (5.1) 10 (6.4) 2 (2.6)
N Eastern Europe and
central Asia
277 (0.4) 8 (0.3) 1 600 (4.8) 0 0 0 2 (0.9) 0 2 (2.6)
N Middle east and North
Africa
99 (0.2) -- -- 0 0 0 0 0 0
N Multiple regions -- 2 (1.1) 2 (2.6) -- 12 (5.1) 12 (7.7) --
RCTs: randomized controlled trials. PT: pharmacologic intervention. NPT: nonpharmacologic intervention. GBD: global burden of disease.
doi:10.1371/journal.pone.0016878.t003
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Forum has highlighted that of the US$73 billion invested annually
in global health research, less than 10% is spent on research into
the health problems that account for 90% of the GBD [4,23,24].
This gap is also reflected in the low proportion of publications
from research performed in low- and middle-income countries
[25].
Contrary to previous research, we focused on 2 public health
priorities (tobacco use, responsible for non-communicable chronic
diseases, and HIV infection, a communicable chronic disease)
relevant for high-, low- and middle-income countries. Our study is
the first to focus on existing evidence (trials included in systematic
reviews) and on awaiting evidence that will guide future evidence-
based practices.
With the evidence of the effectiveness of an intervention, some
might assume that the challenge is to make the intervention
available in low- and middle-income countries [26]. However, the
results of trials performed in high-income countries may not be
easily applied to low- and middle-income countries. Many
interventions shown to be efficacious in high-income countries are
not similarly effective when carried out in other contexts [26,27].
The populations can differ, with people consulting late, frequently
using self-medication, unable or unwilling to adhere to treatment,
and having several co-morbidities (malnourishment, anaemia,
malaria, etc.), in addition to the behavioural and cultural differences
[28,29]. Further, the contextual factors differ greatly, particularly
the social and cultural context, as well as the available facilities and
infrastructures. The lack of studies performed in a relevant location
is particularly problematic for nonpharmacologic interventions
targeting behaviouralchanges (e.g.,education,counselling),because
the results of such trials could be strongly influenced by cultural
conditions [20,30]. The influence of the cultural context is
important, even between different high-income countries [31].
Recently, the Global Alliance for Chronic Disease (GACD) was
created to address this imbalance issue [32]. The GACD brings
together 6 major national health research councils representing
80% of all public research funding in the world to coordinate
research activities that address the prevention and treatment of
chronic disease on a global scale. One essential goal of the GACD
is to focus on chronic disease in low- and middle-income countries
and to coordinate research into low-cost interventions. This
initiative should be important in limiting the worldwide imbalance
in health research resources [7].
Similarly, the High Level Taskforce on Innovative International
Financing for Health Systems was created in September 2008 to
help fill national financing gaps to reach the health Millennium
Development Goals in low-income countries. One key challenge is
to obtain evidence for what works according to different settings
[33].
Our study has some limitations. First, we focused on only 2
medical areas, and these results should be confirmed in other
medical areas. However, we chose tobacco use and HIV infection
because they are among the first 5 causes of mortality in the world
[9]. Second, we selected only RCTs included in Cochrane
systematic reviews because these systematic reviews are known
to be of high quality, and we did not consider non-Cochrane
systematic reviews [34,35,36,37,38]. As well, the Cochrane
collaboration seeks to actively encourage the participation of
reviewers from developing countries and to prioritize reviews
focusing on determinants of health that are particularly pertinent
to low- and middle-income countries [1,4]. Finally, our results may
underestimate the number of ongoing RCTs performed in low-
and middle-income countries because we focused on only available
data (i.e., trials that were registered in a trial registry available on
the WHO portal). We cannot exclude that some trials performed
in low-income countries were not registered.
In conclusion, clinical research into tobacco use and HIV
infection is not performed in the world locations most affected in
terms of GBD and mortality because we found important
underrepresentation of such research in low- and middle-income
countries. The GBD measured by mortality or DALYs could be a
useful aid in deciding where to conduct health research. The
measure should help in conducting RCTs in an appropriate
context to improve clinical research practice and decrease the
GBD [39].
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